Previous 10 | Next 10 |
2023-05-23 10:08:04 ET Gainers: CohBar ( CWBR ) +157% . Ocean Biomedical ( OCEA ) +79% . Shuttle Pharmaceuticals ( SHPH ) +46% . Icosavax ( ICVX ) +31% . Recursion Pharmaceuticals ( RXRX ) +20% . Losers: NantHealth ( ...
2023-05-22 18:06:14 ET Interim phase 1 results of Icosavax's ( NASDAQ: ICVX ) IVX-A12, a bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), showed a robust immune response and was well tolerated. IVX-A12 is composed of IVX-121, a RSV ...
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision...
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was generally well tolerated with no vaccine-related SAEs – – First demonstration of hMPV vaccine immunogenicity in an olde...
2023-05-10 17:43:51 ET Icosavax press release ( NASDAQ: ICVX ): Q1 GAAP EPS of -$0.60 misses by $0.01 . Cash and cash equivalents, restricted cash, and short-term investments as of March 31, 2023 was $197.7 million, compared to $219.4 million for the period ended ...
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at end 1Q 2023 - SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -...
2023-04-11 09:46:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in...
2023-03-31 06:10:53 ET Icosavax press release ( NASDAQ: ICVX ): Q4 GAAP EPS of -$0.59 beats by $0.01 . Cash and cash equivalents, restricted cash, and short-term investments of $219.4M at end 4Q 2022 For further details see: Icosavax GAAP EPS of -$0.59 be...
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023 - - Initiation of IVX-A12 P...
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a visio...
News, Short Squeeze, Breakout and More Instantly...
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
NEW YORK, NY / ACCESSWIRE / February 1, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AVROBIO, Inc. (NASDAQ:AVRO)'s merge...
2024-01-09 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...